Methylenetetrahydrofolate Reductase Polymorphism (677 C>T) Predicts Long Time to Progression in Metastatic Colon Cancer Treated with 5-Fluorouracil and Folinic Acid

Archives of Medical Research

Volumn 41, Issue 6, 2010, Pages 430-435

  Castillo Fernández, Omar ^a   Santibáñez, Miguel ^a   Bauza, Aldo ^a   Calderillo, Germán ^a   Castro, Clementina ^a   Herrera, Roberto ^a   Serrano, Alberto ^a   Arrieta, Oscar ^a   Herrera, Luis A ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

5 FU; Colon cancer; MTHFR; Overall survival; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MALE; MEXICO; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SECTION; WILD TYPE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS;

EID: 78049442304     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.08.011     Document Type: Article

References (28)

1. International Agency for Research on Cancer. Colorectal cancer incidence and mortality worldwide in 2008 (Available at: ). http://www.iarc.fr.
2. Verastegui E., Mohar A. Colorectal cancer in Mexico: should a middle income country invest in screening or in treatment?. Eur J Health Econ 2010, 10(suppl 1):S107-S114.
3. Migdley R., Kerr D. Colorectal cancer. Lancet 1999, 353:391-399.
4. Gill S., Blackstock W., Goldberg R. Colorectal cancer. Mayo Clin Proc 2007, 82:114-129.
5. National Comprehensive Cancer Network. Colon cancer: NCCN clinical practice guidelines in oncology V.3. 2010 (Available at ). http://www.nccn.org.
6. Cals L., Rixe O., Francois E., et al. Dose finding study of weekly 24 h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin and irinotecan in advanced colorectal cancer patients. Ann Oncol 2004, 15:1018-1024.
7. Field K., Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007, 13:3806-3815.
8. Alberts S.R., Wagman L.D. Chemotherapy for colorectal cancer liver metastases. Oncologist 2008, 13:1063-1073.
9. Köhne C.H., Lenz H.J. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009, 14:478-488.
10. Zhang W., Press O.A., Haiman C.A., et al. Association of methylenetethrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol 2007, 25:3726-3731.
11. Marcuello E., Altés A., Memoyo A., et al. Methylenetethrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?. Cancer Chemother Pharmacol 2006, 57:835-840.
12. Friso S., Choi S., Girelli D., et al. A common mutation in the 5,10 methylenetetrahydrofolate reductase gene affects genomics DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002, 99:5606-5611.
13. Goyette P., Pai A., Milos R., et al. Gene structure of human and mouse methylenetethrahydrofolate reductase (MTHFR). Mamm Gen 1998, 9:652-656.
14. Homberger A., Linnebank M., Winter C., et al. Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene. Eur J Hum Genet 2000, 8:725-729.
15. Gusella M., Frigo A.C., Bolzonela C., et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 2009, 100:1549-1557.
16. Derwinger K., Wettergren Y., Odin E., et al. A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer 2009, 8:43-48.
17. Wisotzkey J., Toman J., Bell T., et al. MTHFR (C677T) polymorphism and stage III colon cancer: response to therapy. Mol Diag 1999, 4:95-99.
18. Etienne M., Formento J., Chazal M., et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004, 14:785-792.
19. Yoshiya G., Takahata T., Hanada N., et al. Influence of cancer-related gene polymorphisms on clinicopathological features in colorectal cancer. J Gastronenterol Hepatol 2008, 23:948-953.
20. Sohn K.J., Croxford R., Yates Z., et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004, 96:134-144.
21. Cohen V., Panet R., Sabbaghian N., et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine based chemotherapy. Clin Cancer Res 2003, 9:1611-1615.
22. Jakobsen A., Nederby N., Gydenkerne N., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictor of fluorouracil sensitivity. J Clin Oncol 2005, 23:1365-1369.
23. Suh K.W., Kim J.H., Kim D.Y., et al. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?. Ann Surg Oncol 2006, 13:1379-1385.
24. Ruzzo A., Graziano F., Loupakis F., et al. Phamarmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007, 25:1247-1254.
25. Ruzzo A., Graziano F., Loupakis F., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogen J 2008, 8:278-288.
26. Chua W., Goldstein D., Lee C.K., et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009, 101:998-1004.
27. Etienne-Grimaldi M.C., Milano G., Maindrault-Goebel F., et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 2010, 69:58-66.
28. Gallegos-Arreola M.P., García-Ortíz J.E., Figuera L.E., et al. Association of 677CT polymorphism in the MTHFR gene with colorectal cancer in Mexican patients. Cancer Genomics Proteomics 2009, 6:183-188.